Proof of Concept Data for Treatment of COVID-19 Syndrome with Theaphenon E® Published by Research Group in Rome, Italy

August 2021

Rome, Italy

Professor Saverio Bettuzzi, member of the Istituto Nazionale Biostrutture e Biosistemi of Rome, Italy, has published proof of concept data for the treatment of COVID-19 syndrome with Theaphenon E®, a bioactive plant polyphenol mixture rich in green tea catechins. The treatment aimed to improve respiratory symptoms and reduce inflammation in COVID-19 patients awaiting hospitalization.

Catechins are powerful anti-oxidant, anti-inflammatory and antiviral agents. While awaiting hospitalization, 10 swab-positive patients, symptomatic for SARS-COV-2, were treated for 15 days at home with two sessions of inhalation plus three capsules per day (total catechins: 840 mg; total EGCG: 595 mg). All patients recovered fully and had no symptoms at a median of 9 days, with a range of 7–15 days. Seven switched to a negative SARS- COV-2 nasopharyngeal swab test at a median of 9 days, with a range of 6–13 days. Among the 3 patients still swab-positive, one had a strong decrease of infection down to a “very low” SARS-COV- 2 nucleic acid load at 5 days. All patients exited quarantine at the end of therapy because they were free of symptoms.

In a separate 2020 Italian study of 4480 patients with a positive swab test and date data, the median time to a first negative swab was 31 days from the first positive swab.

These data suggest that Theaphenon E® may reduce COVID-related hospitalizations and accelerate recovery from disease, and the very high rate of positive response observed may open new perspectives in the fight against COVID-19 syndrome.

The results of the study have been published in a peer-reviewed journal: Bettuzzi et al., Efficacy of a Polyphenolic, Standardized Green Tea Extract for the Treatment of COVID-19 Syndrome: A Proof-of-Principle Study. COVID. 2021; 1(1):2-12

Plans to initiate a clinical study with larger number of patients are underway.

About Theaphenon E®:

Theaphenon E® is an improved version of Polyphenon E® that is already in use in 34 clinical trials in the USA and was approved by the FDA in 2006 as the first botanical drug for use against the papilloma virus, under the name of Sinecatechins or Veregen. Theaphenon E® has the highest concentration of relevant catechins in the highest purity currently available and has already been tested for toxicity and safety. It is currently used in Adamas Biotech’s laboratories for further development and implementation for human health. Adamas Biotech is the sole European distributor of Theaphenon E®.


Investor Contact:
Neil Thomas
Cube Labs
+34 60-053-8419

Media Contact:
Isil Guney
Cube Labs
+90 532-502-7243


Close Menu